Loading patent…
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorCarl Saxinger
Estimating the term…
The present invention provides, among other things, a polypeptide, and a pharmaceutically acceptable salt. thereof, that inhibits the binding of IL-6 ligand with IL-6 receptor under physiological conditions, a nucleic acid that encodes such a polypeptide and can be expressed in a cell, a nucleic acid that comprises or encodes an antisense nucleic acid molecule or a ribozyme that is specific for such a polypeptide, an antibody that is specific to such a polypeptide, an anti-antibody thereto, a composition comprising such a polypeptide, nucleic acid, antibody or an anti-body and a carrier therefor, a composition comprising a solid support matrix to which is attached an above-described polypeptide or an anti-antibody to a specified polypeptide sequence, a method of prophylactically or therapeutically inhibiting IL-6 signaling in a mammal in need thereof, a mammal in need thereof, and a method of removing IL-6 ligand from a bodily fluid of an animal.
An isolated polypeptide consisting of a fragment of the IL-6 receptor, wherein said fragment comprises SEQ ID NO:23 or SEQ ID NO:25, wherein said polypeptide inhibits the binding of IL-6 ligand with the IL-6 receptor under physiological conditions and wherein said fragment is not more than 200 contiguous amino acids.
Dependencies are inferred from the claim text.